Trinity Biotech’s CGM+ Platform Flags False Low Alarms Using 5,000-Hour Trial Data
TRIB•Analysis of over 5,000 clinical wear hours from a Q2 2026 pre-pivotal trial shows Trinity Biotech’s CGM+ platform distinguishes compression-related false low glucose events from true hypoglycemia, addressing alarms that occur about once every 5–6 days. The multi-sensor biosensor technology targets a $15 billion global CGM market by providing contextual physiological data beyond glucose.
1. Clinical Trial Validation
Trinity Biotech analyzed approximately 5,000 hours of device wear data from a pre-pivotal Q2 2026 trial with insulin-dependent users to demonstrate that CGM+ can distinguish nocturnal compression-related false low glucose events from true hypoglycemia. These false alarms, occurring roughly once every 5 to 6 days on conventional systems, can disrupt sleep and prompt unnecessary treatment.
2. Multi-Sensor Technology Architecture
The CGM+ platform integrates proprietary sensors for glucose, heart activity, body temperature, and physical activity alongside AI-driven analytics to provide contextual physiological insights. An algorithm processes these signals to identify compression-induced false lows, enhancing accuracy over glucose-only continuous monitoring systems.
3. Market Opportunity and Next Steps
Trinity Biotech positions CGM+ within the $15 billion global CGM market by offering differentiated value to users and automated insulin delivery partners through richer data and reduced false alarms. The platform is in late-stage development and moving toward pivotal trials and regulatory submission.
